C. Lafond

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Robert L. Ferris, Robert I. Haddad, Caroline Even et al. · Annals of Oncology · 2020 · 365 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun et al. · Annals of Oncology · 2022 · 177 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial

Lionnel Geoffrois, Laurent Martin, D. De Raucourt et al. · Journal of Clinical Oncology · 2018 · 148 citations

Medicine, Oncology, Radiation Oncology +15

LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial

Jean Bourhis, Clément Sire, Yungan Tao et al. · Annals of Oncology · 2020 · 65 citations

Medicine, Oncology, Radiation Oncology +9